Novocure Announces Fourth Quarter and Full Year 2018 Operating Statistics, Preliminary Net Revenues and Provides Company Update

Full year 2018 preliminary net revenues of $248.0 million, representing annual growth of more than 40 percent compared to 2017 Fourth quarter and full year 2018 financial results to be reported Thursday, Feb. 28, 2019 ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today reported operating statistics and preliminary, unaudited net revenues and cash balances for …

Novocure to Participate in the 37th Annual J.P. Morgan Healthcare Conference

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) will participate in the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 9, 2019, in San Francisco. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts. He is scheduled to present at 2:30 p.m. PST. A live audio webcast …

Novocure and the AACR Announce Four Inaugural Research Grants to Promote and Support Innovative Research on Tumor Treating Fields

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) and the American Association for Cancer Research (AACR) announce four inaugural Tumor Treating Fields research grants. The grants represent a joint effort to promote and support innovative research on Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to …

Sub-Group Analysis of Novocure’s EF-14 Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Published in Journal of Neuro-Oncology Demonstrating More Time on Optune® Predicted Increased Survival

Patients who used Optune more than 90 percent of the time experienced a median overall survival of 24.9 months Monthly usage was a predictor of survival, independent of other prognostic factors such as Karnofsky Performance Score, age, or MGMT methylation status ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that the results of a retrospective …

Novocure and Zai Lab Awarded Deal of the Year at 5th Annual BioCentury China Healthcare Summit in Shanghai, China

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that Novocure and Zai Lab have received the Deal of the Year Award from BayHelix at a ceremony during the 5th annual BioCentury China Healthcare Summit in Shanghai, China. The award is part of the BayHelix China Healthcare Awards series, celebrating outstanding individuals and companies for their …

Novocure Announces More than 70 Presentations on Tumor Treating Fields at 23rd Annual Meeting of the Society for Neuro-Oncology

Presentations span 21 research areas with five oral presentations More than 50 presentations from external authors indicate a growing interest Novocure’s proprietary Tumor Treating Fields platform ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced more than 70 presentations on Tumor Treating Fields, including five oral presentations, will be featured at the 23rd Annual Meeting …

Novocure and Zai Lab to Host Investor Event

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will host an investor event with Zai Lab on Nov. 14, 2018, in Shanghai, China. William Doyle, Novocure’s Executive Chairman, Dr. Samantha Du, Zai Lab’s CEO, and Tao Fu, Zai Lab’s President and Chief Operating Officer, will review the strategic collaboration for Tumor Treating …

Novocure Reports Third Quarter 2018 Financial Results and Provides Company Update

Quarterly net revenues of $64.8 million, representing 29 percent growth versus the third quarter 2017 and 5 percent growth versus the second quarter 2018 Humanitarian device exemption (HDE) application submitted to FDA for approval in malignant pleural mesothelioma ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today reported financial results for the three and nine months …

Novocure Founder Professor Yoram Palti and Director Louis J. Lavigne, Jr. Retire from Board of Directors

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today the retirement of Novocure founder Professor Yoram Palti, MD, PhD, and director Louis J. Lavigne, Jr. from the board of directors effective October 24, 2018. Professor Palti invented Tumor Treating Fields and founded Novocure in 2000. He serves as the company’s Chief Technology Officer (CTO) and …

Higher Delivered Dose of Tumor Treating Fields to Tumor Bed Associated with Improved Overall Survival in Newly Diagnosed Glioblastoma

Post-hoc analysis of EF-14 phase 3 pivotal trial demonstrated that power loss density and electric field intensity were associated with improved overall survival, independent of compliance This is the first analysis to quantify the delivered dose of Tumor Treating Fields, defined as a function of both power loss density and monthly usage of therapy Patients …